Augmedix, Inc. Quarterly Debt-to-equity in % from Q3 2019 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Augmedix, Inc. quarterly Debt-to-equity history and growth rate from Q3 2019 to Q2 2024.
  • Augmedix, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 322 %, a 79.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 322 -1.27K -79.8% Jun 30, 2024
Q1 2024 360 -428 -54.3% Mar 31, 2024
Q4 2023 642 +325 +103% Dec 31, 2023
Q3 2023 4.94K +4.75K +2478% Sep 30, 2023
Q2 2023 1.59K +1.36K +570% Jun 30, 2023
Q1 2023 788 +429 +119% Mar 31, 2023
Q4 2022 317 -655 -67.4% Dec 31, 2022
Q3 2022 192 +1.26K Sep 30, 2022
Q2 2022 238 +338 Jun 30, 2022
Q1 2022 359 +394 Mar 31, 2022
Q4 2021 972 +984 Dec 31, 2021
Q3 2021 -1.07K -1.06K -11063% Sep 30, 2021
Q2 2021 -99.8 -86.7 -660% Jun 30, 2021
Q1 2021 -35 -14.9 -73.9% Mar 31, 2021
Q4 2020 -11.6 +30 +72% Dec 31, 2020
Q3 2020 -9.61 +96.4 +90.9% Sep 30, 2020
Q2 2020 -13.1 Jun 30, 2020
Q1 2020 -20.1 Mar 31, 2020
Q4 2019 -41.6 Dec 31, 2019
Q3 2019 -106 Sep 30, 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.